Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study

Yin, Peng1; Meng, Juan2; Chen, Jincheng3; Gao, Junxiao1; Wang, Dongqi1; Liu, Shuyan2; Guo, Qinglong2; Zhu, Muchun1; Zhang, Gengwei2; Liu, Yingxia2,3; Li, Ye1; Zhang, Guoliang2

2021-07-08

10.1186/s12985-021-01617-w

VIROLOGY JOURNAL   影响因子和分区

1743-422X

Objectives The aim of this study was to evaluate the role of antiviral drugs in reducing the risk of developing severe illness in patients with moderate COVID-19 pneumonia. Methods This retrospective cohort study included 403 adult patients with moderate COVID-19 pneumonia who were admitted to Shenzhen Third People's Hospital, China. The antiviral drugs arbidol, interferon alpha-1b, lopinavir-ritonavir and ribavirin were distributed to the patients for treatment. The primary endpoint of this study was the time to develop severe illness. Results Of the 462 patients admitted, 403 had moderate COVID-19 symptoms at hospital admission and were included in this study. 90 of the 403 (22.3%) patients progressed to severe illness. The use of arbidol was associated with a lower severity rate 3.5% compared to control group 30.5%, p-value < 0.0001; the adjusted hazard ratio was 0.28 (95% CI: 0.084-0.90, p = 0.033). The use of interferon alpha-1b was associated with a lower severity rate 15.5% compared to control group 29.3%, with p-value < 0.0001; the adjusted hazard ratio was 0.30 (95% CI: 0.15-0.58, p = 0.0005). The use of lopinavir-itonavir and ribavirin did not show significant differences in adjusted regression models. Early use of arbidol within 7 days of symptom onset was significantly associated with a reduced recovery time of - 5.2 days (IQR - 3.0 to - 7.5, p = 4e-06) compared with the control group. Conclusion Treatment with arbidol and interferon alpha-1b contributes to reducing the severity of illness in patients with moderate COVID-19 pneumonia. Early use of arbidol may reduce patients' recovery time.

Arbidol Interferon alpha-1b Severity rate COVID-19 Antiviral agents

SCI

英语

通讯

National Natural Science Foundation of China[11801542] ; Shenzhen Fundamental Research Project[JCYJ20180703145002040] ; Strategic Priority Research Program of Chinese Academy of Sciences[XDB 38040200] ; Shenzhen Scientific and Technological Project["JSGG20200225150702770","JSGG20200225153023511"] ; Guangdong Scientific and Technological Project[2020B1111340076] ; Shenzhen Bay Laboratory Open Research Program[SZBL202002271003]

Virology

Virology

WOS:000671323600001

BMC

Web of Science

1.Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China
2.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis, Shenzhen 518112, Peoples R China
3.Univ Chinese Acad Sci, Savaid Med Sch, Beijing 100049, Peoples R China

Yin, Peng,Meng, Juan,Chen, Jincheng,et al. Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study[J]. VIROLOGY JOURNAL,2021,18(1).

Yin, Peng.,Meng, Juan.,Chen, Jincheng.,Gao, Junxiao.,Wang, Dongqi.,...&Zhang, Guoliang.(2021).Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study.VIROLOGY JOURNAL,18(1).

Yin, Peng,et al."Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study".VIROLOGY JOURNAL 18.1(2021).